American University Washington College of Law

Robert Wood Johnson Fellowship Healthcare Finance

The Johns Hopkins University

University of the Witwatersrand

Co-Founder and President at Popper and Company;
JD

Infinity Bio, Inc.

Senior Advisor and Board Member, 

Clinical Microbiomics

Director, Board Member

Riverside Partners

Advisory Board Member

Chair, Innovation and Commercialization Committee
Member, Center for Public Health and Human Rights Advisory Committee

Johns Hopkins Bloomberg School of Public Health

Popper and Company works with clients at the convergence of life sciences and technology, who are interested in improving the efficiency of our healthcare system. We place particular focus on leveraging technology and new biological insights to generate  information to improve healthcare at the researcher, provider, payor and patient/consumer level. We’re made up of a team of diverse professionals – physician entrepreneurs across multiple disciplines, engineers, scientists, marketers and clinicians – each with a unique perspective and problem-solving capabilities.
Our strategic insights chart a clear path forward and help your company gain a competitive edge by leveraging information and analysis into informed business decisions.

As Co-Founder and President, I provide strategic and tactical advice to large public and small private companies – as well as private equity and venture investors around the world. I’m passionate about developing robust strategies, finding creative solutions, and assembling ideas in innovative new ways.

Popper and Company

Co-Founder and President

Infinity Bio provides the most granular insights into the antibody context of individuals and populations leveraging  its proprietary antibody profiling technology (MIPSA, from the lab of Assoc. Prof Ben Larman, Johns Hopkins)

Infinity Bio Inc

Chief Executive Officer

Leading early phase clinical CRO in APAC serving pharma innovators globally
Acquired by the Riverside Company

Avance Clinical

Board Member

Advising Hopkins leaders on leveraging uniquely complete Hopkins datasets and extensive institutional expertise to truly deliver on the promise of precision medicine and derive quality and financial benefits

Johns Hopkins inHealth Precision Medicine

Advisor and Chief Commercialization Officer inHealth

Agilex Biolabs Pty Ltd

Science-driven microbiome analysis company serving drug developers and innovators with microbiome insights derived from metagenomic analysis of all organisms in a specimen agnostic manner.

Diversigen, Inc.

Chairman and CEO

US Department of Health and Human Services

External Advisor, Innovation Fellows Program

Private equity- backed bioanalytical lab focused on accelerating large molecule therapeutics into the market successfully exited to Cobepa

BioAgilytix

Public Australian company building hardware and software solutions to improve efficiency of various healthcare practices, leveraging core competence in machine learning

LBT Innovations (Australia)

Private equity backed company providing enterprise quality management tools for life science companies
Successful exit to major strategic

Pilgrim Quality Solutions

bioMerieux

Strategy & Business Development

Responsible for business and commercialization functions including strategy development, business development (from scouting through detailed analysis negotiation and closing), relationship management with key strategic partners, marketing and communications (internal, external, investor)

MDS Proteomics

Chief Business Officer

Responsible for strategy creation and implementation, through internal and external development of new business for Becton Dickinson in the high-growth segment of molecular diagnostics, which was integral to the company’s long-term growth strategy

Caroline Popper M.D. MPH J.D.